Peter Drueckes

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 489 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +14

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 447 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

Paul W. Manley, Peter Drueckes, Gabriele Fendrich et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 2009 · 222 citations

Life Sciences, Medicinal Chemistry, Pharmacology +12

A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients

Ralph Tiedt, Elisa Degenkolbe, Pascal Furet et al. · Cancer Research · 2011 · 135 citations · Full text

Medicine, Oncology, Pharmacology +14

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

Fabienne Baffert, Catherine H. Régnier, Alain De Pover et al. · Molecular Cancer Therapeutics · 2010 · 120 citations

Medicine, Molecular Biology, Pharmacology +13